Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lam

Showing results (1361-1370 of 1,417) with videos related to

Pageof 142
Sort By:
ACS Medicinal Chemistry Letters|September 18, 2024
Conformationally Constrained Isoquinolinones as Orally Efficacious Hepatitis B Capsid Assembly ModulatorsEugen F Mesaros, Andrew G Cole, Steven G Kultgen, et al.
Journal of Medicinal Chemistry|November 8, 2024
Structure-Activity Relationships and Discovery of (<i>S</i>)-5-(<i>tert</i>-Butyl)-11-(difluoromethoxy)-9-methoxy-2-oxo-1,2,5,6-tetrahydropyrido[2',1':2,3]imidazo[4,5-<i>h</i>]quinoline-3-carboxylic Acid (AB-161), a Novel Orally Available and Liver-Centric HBV RNA DestabilizerDimitar Gotchev, Shuai Chen, Benjamin Dugan, et al.
Intellectual and Developmental Disabilities|May 24, 2019
Exploring the Valley of Savings: Minimizing Part D Costs and Optimizing Drug Therapy Outcomes in Medicare Beneficiaries With Developmental DisabilityEdward L Rogan, Carly A Ranson, Traci K Mori, et al.
Journal of Medicinal Chemistry|September 18, 2010
Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virusMichael J Sofia, Donghui Bao, Wonsuk Chang, et al.
ACS Infectious Diseases|September 22, 2024
Control of Hepatitis B Virus with Imdusiran, a Small Interfering RNA TherapeuticEmily P Thi, Xin Ye, Nicholas M Snead, et al.
Antimicrobial Agents and Chemotherapy|March 30, 2011
Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methylguanosineAngela M Lam, Christine Espiritu, Eisuke Murakami, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of PSI-353661, a Novel Purine Nucleotide Prodrug for the Treatment of HCV InfectionWonsuk Chang, Donghui Bao, Byoung-Kwon Chun, et al.
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi|September 29, 2012
The CEPHEUS Pan-Asian survey: high low-density lipoprotein cholesterol goal attainment rate among hypercholesterolaemic patients undergoing lipid-lowering treatment in a Hong Kong regional centreRaymond H W Chan, P H Chan, Kelvin K W Chan, et al.
Antimicrobial Agents and Chemotherapy|April 25, 2012
Metabolic activation of the anti-hepatitis C virus nucleotide prodrug PSI-352938Congrong Niu, Tatiana Tolstykh, Haiying Bao, et al.
Journal of Virology|June 30, 2021
Host Poly(A) Polymerases PAPD5 and PAPD7 Provide Two Layers of Protection That Ensure the Integrity and Stability of Hepatitis B Virus RNAFei Liu, Amy C H Lee, Fang Guo, et al.
Pageof 142

Showing results (1361-1370 of 1,417) with videos related to

Sort By:
Pageof 142
ACS Medicinal Chemistry Letters|September 18, 2024
Conformationally Constrained Isoquinolinones as Orally Efficacious Hepatitis B Capsid Assembly ModulatorsEugen F Mesaros, Andrew G Cole, Steven G Kultgen, et al.
Journal of Medicinal Chemistry|November 8, 2024
Structure-Activity Relationships and Discovery of (<i>S</i>)-5-(<i>tert</i>-Butyl)-11-(difluoromethoxy)-9-methoxy-2-oxo-1,2,5,6-tetrahydropyrido[2',1':2,3]imidazo[4,5-<i>h</i>]quinoline-3-carboxylic Acid (AB-161), a Novel Orally Available and Liver-Centric HBV RNA DestabilizerDimitar Gotchev, Shuai Chen, Benjamin Dugan, et al.
Intellectual and Developmental Disabilities|May 24, 2019
Exploring the Valley of Savings: Minimizing Part D Costs and Optimizing Drug Therapy Outcomes in Medicare Beneficiaries With Developmental DisabilityEdward L Rogan, Carly A Ranson, Traci K Mori, et al.
Journal of Medicinal Chemistry|September 18, 2010
Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virusMichael J Sofia, Donghui Bao, Wonsuk Chang, et al.
ACS Infectious Diseases|September 22, 2024
Control of Hepatitis B Virus with Imdusiran, a Small Interfering RNA TherapeuticEmily P Thi, Xin Ye, Nicholas M Snead, et al.
Antimicrobial Agents and Chemotherapy|March 30, 2011
Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methylguanosineAngela M Lam, Christine Espiritu, Eisuke Murakami, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of PSI-353661, a Novel Purine Nucleotide Prodrug for the Treatment of HCV InfectionWonsuk Chang, Donghui Bao, Byoung-Kwon Chun, et al.
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi|September 29, 2012
The CEPHEUS Pan-Asian survey: high low-density lipoprotein cholesterol goal attainment rate among hypercholesterolaemic patients undergoing lipid-lowering treatment in a Hong Kong regional centreRaymond H W Chan, P H Chan, Kelvin K W Chan, et al.
Antimicrobial Agents and Chemotherapy|April 25, 2012
Metabolic activation of the anti-hepatitis C virus nucleotide prodrug PSI-352938Congrong Niu, Tatiana Tolstykh, Haiying Bao, et al.
Journal of Virology|June 30, 2021
Host Poly(A) Polymerases PAPD5 and PAPD7 Provide Two Layers of Protection That Ensure the Integrity and Stability of Hepatitis B Virus RNAFei Liu, Amy C H Lee, Fang Guo, et al.
Pageof 142